FY2014 Press Release

"I'm proud to report a strong finish to a year highlighted by significant business and financial progress," said Codexis President and CEO John Nicols. "In December we received our first milestone payment under a non-exclusive licensing agreement with GSK that we announced last July. The technology transfer process is progressing well and we expect to receive an additional milestone and to initiate new projects in 2015.

"We met all of our financial guidance metrics for 2014. We grew revenues to more than $35 million, improved gross margin to 72% from 54% in the prior year and reported cash, cash equivalents and short-term investments at December 31, 2014 of $26.5 million compared with $25.1 million at December 31, 2013. We also continued to build momentum in the business by closing out the year with another quarter of significant R&D revenue growth, introducing our novel enzyme therapeutic candidate for PKU, and expanding our customer base in both the pharmaceuticals and food industries.

"We believe we are well positioned for another year of growth in 2015 and continued movement toward profitability," added Nicols. "We have the ability to engineer novel proteins quickly and efficiently which helps our clients to manufacture their products more efficiently. We address a significant market opportunity with the ability to reduce costs for pharmaceutical clients and deliver value in many additional applications."

Total revenues for the quarter ended December 31, 2014 increased 49% to $14.2 million from $9.5 million for the fourth quarter of 2013. Revenues were comprised of $4.7 million in biocatalyst product sales, $7.8 million in biocatalyst research and development revenue, which included a $5.0 million milestone payment from the GSK licensing agreement, and $1.7 million from the revenue-sharing arrangement with Exela Pharma Sciences for sales of argatroban injectable drug. Total revenues in the fourth quarter of 2013 included biocatalyst product sales of $3 million to a major pharmaceutical customer.

Research and development expenses for the fourth quarter of 2014 decreased by $3.8 million, or 43%, to $5.0 million, due primarily to a $1.6 million write down recorded in the fourth quarter of 2013 related to the winding down of the company's biofuels business, and lower employee-related costs associated with the company's restructuring implemented in late 2013. Selling, general and administrative expenses in the fourth quarter of 2014 decreased 11% to $5.1 million compared with the same period of 2013 due mainly to reductions in employee-related expenses and other discretionary expenses.

Net income for the fourth quarter of 2014 of $0.3 million, or $0.01 per basic and diluted share, compared favorably with a net loss of $9.8 million, or $0.26 per basic and diluted share, for the fourth quarter of 2013. Non-GAAP adjusted net income was $2.8 million, or $0.07 per basic and diluted share, a significant improvement from a non-GAAP adjusted net loss of $4.7 million, or $0.12 per basic and diluted share, reported for the fourth quarter of 2013.

Research and development expenses for 2014 of $22.8 million decreased 28% from the prior year, resulting primarily from lower employee-related expenses associated with the company-wide restructuring implemented in late 2013, and decreased depreciation expense resulting from the disposal and impairment of certain equipment previously used in discontinued R&D activities. Selling, general and administrative expenses for 2014 decreased 18% to $21.9 million compared with 2013, due mainly to lower employee-related expenses, consulting and outside services.

Consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. On a non-GAAP basis, financial measures exclude non-cash items such as depreciation expense, amortization expense and stock-based compensation expense, as well as one-time non-cash impairment and change in fair value of assets held for use. Non-GAAP financial measures presented are: non-GAAP net income/loss, non-GAAP net income/loss per share, non-GAAP research and development expense and non-GAAP selling, general and administrative expense. Non-GAAP operating expenses exclude employee stock-based compensation expense, amortization of intangible assets, depreciation of fixed assets, the impairment of certain lab equipment used in research and development activities, a decrease in fair value of assets held for sale and the gain on sale of Codexis' former Hungarian subsidiary.

Codexis management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an ongoing basis, and internally for operating, budgeting and financial planning purposes. Codexis management believes the non-GAAP information is useful for investors by offering the ability to identify trends in what management considers to be Codexis' core operating results and to better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Codexis. These non-GAAP financial measures are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP, and therefore these non-GAAP results should only be used for evaluation in conjunction with the corresponding GAAP measures. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Financial Measures."

A recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing 888-286-8010 for domestic callers or 617-801-6888 for international callers. Please use the passcode 94888240 to access the replay. A webcast replay will be available on the Investors section of www.codexis.com for 30 days, beginning approximately two hours after the completion of the call.

This press release contains forward-looking statements relating to Codexis’ forecast for 2015 total revenues and gross margins as a percent of total revenue and Codexis' belief that it will receive a milestone payment and initiate new projects in 2015 under its non-exclusive licensing agreement with GSK. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include Codexis’ need for substantial additional capital in the future in order to expand its business; Codexis’ dependence on its collaborators; Codexis’ dependence on a limited number of products and customers in its pharmaceutical business; potential adverse effects to Codexis’ business if its customers’ pharmaceutical products are not received well in the markets; Codexis’ ability to develop and commercialize new products for the pharmaceutical markets; Codexis’ ability to deploy its technology platform in new market spaces; any impairments Codexis may be required to record in the future with respect to its goodwill, intangible assets or other long-lived assets; Codexis’ pharmaceutical product gross margins are variable and may decline from quarter to quarter; Codexis’ dependence on one contract manufacturer for large-scale production of its enzymes; and Codexis' dependence on key personnel. Additional factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2014 and Quarterly Reports on Form 10-Q filed with the SEC on May 8, 2014, August 8, 2014 and November 6, 2014, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.



	Three Months Ended						Twelve Months Ended
	December 31, 2014			December 31, 2013			December 31, 2014			December 31, 2013
Revenues:
Biocatalyst product sales	$	4,741		$	5,263		$	13,064		$	20,423
Biocatalyst research and development	7,769			1,931			14,945			6,868
Revenue sharing arrangement	1,681			2,331			7,298			4,631
Total revenues	14,191			9,525			35,307			31,922
Costs and operating expenses:
Cost of biocatalyst product revenues	3,547			4,764			9,726			14,554
Research and development	5,047			8,829			22,755			31,606
Selling, general and administrative	5,147			5,783			21,937			26,908
Total costs and operating expenses	13,741			19,376			54,418			73,068
Income (loss) from operations	450			(9,851		)	(19,111		)	(41,146		)
Interest income	3			8			18			60
Other expense	(50		)	(15		)	(234		)	(304		)
Income (loss) before income taxes	403			(9,858		)	(19,327		)	(41,390		)
Benefit from income taxes	(58		)	(45		)	(256		)	(87		)
Net income (loss)	$	345		$	(9,813	)	$	(19,071	)	$	(41,303	)
Net income (loss) per share, basic and diluted	$	0.01		$	(0.26	)	$	(0.50	)	$	(1.08	)
Shares used in computing basic earnings (loss) per share	38,641			38,329			38,209			38,231
Shares used in computing diluted earnings (loss) per share	39,592			38,329			38,209			38,231



	December 31,
	2014			2013
Assets
Current assets:
Cash and cash equivalents	$	26,487		$	22,130
Short-term investments	—			3,005
Accounts receivable, net	3,870			5,413
Inventories	1,395			1,487
Prepaid expenses and other assets, current	1,255			1,567
Assets held for sale	—			2,179
Total current assets	33,007			35,781
Restricted cash	711			711
Marketable securities	688			795
Property and equipment, net	3,995			8,446
Intangible assets, net	6,186			9,560
Goodwill	3,241			3,241
Other assets, non-current	294			306
Total assets	$	48,122		$	58,840
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	4,673		$	3,961
Accrued compensation	2,946			3,625
Other accrued liabilities	2,619			1,612
Deferred revenues	3,497			2,001
Total current liabilities	13,735			11,199
Deferred revenues, net of current portion	3,813			1,114
Other liabilities	4,263			5,044
Total liabilities	21,811			17,357
Stockholders’ equity:
Common stock	4			4
Additional paid-in capital	302,379			298,370
Accumulated other comprehensive loss	(142		)	(32		)
Accumulated deficit	(275,930		)	(256,859		)
Total stockholders’ equity	26,311			41,483
Total liabilities and stockholders’ equity	$	48,122		$	58,840



	Three Months Ended						Twelve Months Ended
	December 31, 2014			December 31, 2013			December 31, 2014			December 31, 2013
(i) Research and development expenses
Research and development expenses - GAAP	$	5,047		$	8,829		$	22,755		$	31,606
Non-GAAP adjustments:
Impairment of excess lab equipment and change in fair value of assets held for sale(a)	—			(1,582		)	(2,728		)	(1,582		)
Gain on sale of Hungarian subsidiary(b)	—			—			760			—
Depreciation expense(c)	(388		)	(1,321		)	(2,233		)	(5,453		)
Intangible asset amortization (d)	(844		)	(844		)	(3,374		)	(3,374		)
Employee stock-based compensation(e)	(219		)	(212		)	(953		)	(1,201		)
Research and development expenses - Non-GAAP	$	3,596		$	4,870		$	14,227		$	19,996

(ii) Selling, general and administrative expenses
Selling, general and administrative expenses - GAAP	$	5,147		$	5,783		$	21,937		$	26,908
Non-GAAP adjustments:
Depreciation expense(c)	(244		)	(317		)	(1,078		)	(1,491		)
Employee stock-based compensation(e)	(771		)	(816		)	(3,667		)	(3,188		)
Selling, general and administrative expenses - Non-GAAP	$	4,132		$	4,650		$	17,192		$	22,229

(iii) Net income (loss)
Net income (loss) - GAAP	$	345		$	(9,813	)	$	(19,071	)	$	(41,303	)
Non-GAAP adjustments:
Impairment of excess lab equipment and change in fair value of assets held for sale(a)	—			1,582			2,728			1,582
Gain on sale of Hungarian subsidiary(b)	—			—			(760		)	—
Depreciation expense(c)	632			1,638			3,311			6,944
Intangible asset amortization(d)	844			844			3,374			3,374
Employee stock-based compensation(e)	990			1,028			4,620			4,389
Net income (loss) - Non-GAAP	$	2,811		$	(4,721	)	$	(5,798	)	$	(25,014	)

(iv) Earnings (loss) per share
GAAP earnings (loss) per share - basic and diluted	$	0.01		$	(0.26	)	$	(0.50	)	$	(1.08	)
Adjustments to GAAP net income (loss) (as detailed above)	0.06			0.14			0.35			0.43
Non-GAAP earnings (loss) per share - basic and diluted	$	0.07		$	(0.12	)	$	(0.15	)	$	(0.65	)

(a) Impairment of excess lab equipment and change in fair value of assets held for sale: we provide non-GAAP information which excludes expenses for the impairment of excess lab equipment and the changes in fair values of assets held for sale because they do not relate to the normal and recurring transactions of Codexis' business; such exclusion facilitates comparisons of Codexis' operating results to peer companies.

(c) Depreciation expense: we provide non-GAAP information which excludes depreciation expense related to the depreciation of property and equipment. We believe that eliminating this expense from our non-GAAP measures is useful to investors, because the acquisition of property and equipment, and the corresponding depreciation expense, can be inconsistent in amount and can vary from period to period.

(d) Intangible asset amortization: we provide non-GAAP information which excludes expenses for the amortization of intangible assets which primarily relate to purchased intangible assets associated with our acquisitions. We believe that eliminating this expense from our non-GAAP measures is useful to investors, because this expense is non-cash and such exclusion facilitates comparisons of Codexis' operating results to peer companies.

(e) Employee stock-based compensation: we provide non-GAAP information which excludes expenses for stock-based compensation. We believe the exclusion of this item allows for financial results that are more indicative of our continuing operations. We also believe that the exclusion of stock-based compensation expense provides for a better comparison of Codexis' operating results to prior periods and to our peer companies as the calculations of stock-based compensation vary from period to period and company to company due to different valuation methodologies, subjective assumptions and the variety of award types.


•	Total revenues of $39 million to $42 million, representing a 10% to 19% increase over 2014. This revenue guidance assumes recognizing a $6.5 million milestone related to the company's non-exclusive licensing agreement with GSK expected towards the end of 2015.


•	Continued gross margins as a percent of total sales in the range of 70% to 75%.